<DOC>
	<DOCNO>NCT01688960</DOCNO>
	<brief_summary>This open-label , multicenter , ascend , multiple dose study nesvacumab ( REGN910/ SAR307746 ) combination aflibercept ( `` ziv-aflibercept '' U.S . )</brief_summary>
	<brief_title>Nesvacumab ( REGN910/ SAR307746 ) Aflibercept ( `` Ziv-aflibercept '' U.S. ) Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion include , limited , follow : 1 . Confirmed diagnosis solid tumor malignancy 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 3 . Adequate hepatic , renal bone marrow function 4 . Resolution toxicity prior therapy ( except alopecia ) grade le equal 1 Exclusion criterion include , limited , follow : 1 . Patients brain metastasis , spinal cord compression , carcinomatous meningitis , evidence central nervous system involvement 2 . Either systolic BP great 140 mm Hg diastolic BP great 90 mm Hg 3 . Patients medical history myocardial infarction , unstable angina pectoris , coronary/ peripheral artery bypass graft , congestive heart failure ventricular arrhythmia 4 . Patients deep vein thrombosis pulmonary embolism within last 3 month 5 . Patients serious non heal wound acute ulcer 6 . Patients treatment resistant bleeding peptic ulcer disease , erosive esophagitis gastritis , grade 3 gastrointestinal bleeding/hemorrhage , infectious inflammatory bowel disease , diverticulitis , uncontrolled thromboembolic event within last 3 month 7 . Patients history abdominal trachealesophageal fistula 8 . Prior treatment aflibercept ( zivaflibercept ) , Ang2 Tie2 inhibitor 9 . Prior treatment bevacizumab within last 6 week 10 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>